| Schedule of Disaggregated Revenue |
The following table presents our disaggregated revenue for the periods presented (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
MRD revenue |
|
|
|
|
|
|
|
|
|
|
|
|
Service revenue |
|
$ |
66,168 |
|
|
$ |
44,438 |
|
|
$ |
124,261 |
|
|
$ |
83,659 |
|
Regulatory milestone revenue |
|
|
— |
|
|
|
5,500 |
|
|
|
9,000 |
|
|
|
10,000 |
|
Total MRD revenue |
|
|
66,168 |
|
|
|
49,938 |
|
|
|
133,261 |
|
|
|
93,659 |
|
Immune Medicine revenue |
|
|
|
|
|
|
|
|
|
|
|
|
Service and licensing revenue |
|
|
5,385 |
|
|
|
5,001 |
|
|
|
9,166 |
|
|
|
10,123 |
|
Collaboration revenue(1) |
|
|
— |
|
|
|
3,940 |
|
|
|
— |
|
|
|
7,540 |
|
Total Immune Medicine revenue |
|
|
5,385 |
|
|
|
8,941 |
|
|
|
9,166 |
|
|
|
17,663 |
|
Total revenue |
|
$ |
71,553 |
|
|
$ |
58,879 |
|
|
$ |
142,427 |
|
|
$ |
111,322 |
|
(1) On August 13, 2025, the Genentech Agreement was terminated, with termination effective February 9, 2026.
|